T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade

Nephrology Dialysis Transplantation

Volumn 26, Issue 3, 2011, Pages 1087-1093

  Grimbert, Philippe ^a   Audard, Vincent ^a   Diet, Carine ^a   Matignon, Marie ^a   Plonquet, Anne ^b   Mansour, Hicham ^a   Desvaux, Dominique ^a   Durrbach, Antoine ^c   Cohen, José Laurent ^b   Lang, Philippe ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Belatacept; T cell phenotype; Treg

Indexed keywords

BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 17; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; BIOPSY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; TRANSPLANTATION TOLERANCE;

EID: 79952165892     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq453     Document Type: Article

References (33)

1. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (Belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5:443-453 (Pubitemid 40313335)
2. Rietz C, Chen L. New B7 family members with positive and negative costimulatory function. Am J Transplant 2004;4:8-14 (Pubitemid 38155484)
3. Bluestone JA. CTLA-4Ig is finally making it: a personal perspective. Am J Transplant 2005;5:423-424 (Pubitemid 40313331)
4. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with Belatacept in renal transplantation. N Engl J Med 2005;353:770-781 (Pubitemid 41215486)
5. Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008;8:2086-2096
6. Chavez H, Beaudreuil S, Abbed K et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007;17:243-248 (Pubitemid 46687025)
7. Bouguermouh S, Fortin G, Baba N et al. CD28 co-stimulation down regulates Th17 development. PLoS ONE 2009;4: e5087
8. Yuan X, Paez-Cortez J, Schmitt-Knosalla I et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008;205:3133-3144
9. Ashton-Chess J, Giral M, Soulillou JP et al. Using biomarkers of tolerance and rejection to identify high-and low-risk patients following kidney transplantation. Transplantation 2009;87: S95-S99
10. Mansour H, Homs S, Desvaux D et al. Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol 2008;19:2277-2281
11. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005;353:2342-2351 (Pubitemid 41713746)
12. Bestard O, Cruzado JM, Rama I et al. Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008;19:2020-2026
13. Hoffmann SC, Hale DA, Kleiner de et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005;5:573-581 (Pubitemid 40313350)
14. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006;6:2006-2012 (Pubitemid 44199535)
15. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-760 (Pubitemid 351347767)
16. Gao W, Lu Y, El Essawy B et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007;7:1722-1732 (Pubitemid 46905432)
17. Zeiser R, Nguyen VH, Beilhack A et al. Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006;108:390-399 (Pubitemid 43990654)
18. Guo F, Iclozan C, Suh WK et al. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008;181:2285-2291
19. Tang Q, Henriksen KJ, Boden EK et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003;171:3348-3352 (Pubitemid 37254533)
20. Yeung MY, Sayegh MH. Regulatory T cells in transplantation: what we know and what we do not know. Transplant Proc 2009;41: S21-S26
21. Graziotto R, Del Prete D, Rigotti P et al. Perforin, Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft rejection: analyses on serial biopsies suggest methodological issues. Transplantation 2006;81:1125-1132
22. Dijke IE, Caliskan K, Korevaar SS et al. FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. Transpl Immunol 2008;18:250-254 (Pubitemid 350151856)
23. Stockinger B, Barthlott T, Kassiotis G. The concept of space and competition in immune regulation. Immunology 2004;111:241-247 (Pubitemid 38365744)
24. Eisenberger U, Seifried A, Patey N et al. FoxP3 positive T cells in graft biopsies from living donor kidney transplants after donorspecific transfusions. Transplantation 2009;87:138-142
25. Martin L, Funes de la Vega M, Bocrie O et al. Detection of Foxp3+ cells on biopsies of kidney transplants with early acute rejection. Transplant Proc 2007;39:2586-2588 (Pubitemid 47588396)
26. Bunnag S, Allanach K, Jhangri GS et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant 2008;8:1423-1433 (Pubitemid 351989494)
27. Taflin C, Nochy D, Hill G et al. Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function. Transplantation 2010;89:194-199
28. Veronese F, Rotman S, Smith RN et al. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant 2007;7:914-922 (Pubitemid 46481190)
29. Bestard O, Cruzado JM, Mestre M et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007;179:4901-4909
30. Vicenti F, Grinyo JM, Charpentier B et al. Primary outcomes from a randomized phase III study of Belatacept vs cyclosporine in kidney transplant recipients (BENEFIT study). Transpl Int 2009;22:89
31. Bahri R, Naji A, Menier C et al. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 2009;183:7054-7062
32. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861 (Pubitemid 47240944)
33. Ashton-Chess J, Dugast E, Colvin RB et al. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009;20:1113-1122